Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Quentin M Anstee

Showing results (191-200 of 261) with videos related to

Pageof 27
Sort By:
Cancers|April 3, 2021
A <i>PDCD1</i> Role in the Genetic Predisposition to NAFLD-HCC?Nardeen Eldafashi, Rebecca Darlay, Ruchi Shukla, et al.
The Lancet. Gastroenterology & Hepatology|August 9, 2020
A blood-based biomarker panel (NIS4) for non-invasive diagnosis of non-alcoholic steatohepatitis and liver fibrosis: a prospective derivation and global validation studyStephen A Harrison, Vlad Ratziu, Jérôme Boursier, et al.
The American Journal of Gastroenterology|May 27, 2020
Presence of Serum Antinuclear Antibodies Does Not Impact Long-Term Outcomes in Nonalcoholic Fatty Liver DiseaseRamy Younes, Olivier Govaere, Salvatore Petta, et al.
Nature Medicine|July 21, 2025
Modulation of metabolic, inflammatory and fibrotic pathways by semaglutide in metabolic dysfunction-associated steatohepatitisMaximilian Jara, Jenny Norlin, Mette Skalshøi Kjær, et al.
Canadian Liver Journal|August 22, 2022
Current considerations for clinical management and care of non-alcoholic fatty liver disease: Insights from the 1st International Workshop of the Canadian NASH Network (CanNASH)Giada Sebastiani, Keyur Patel, Vlad Ratziu, et al.
Journal of Hepatology|May 15, 2021
Diagnostic accuracy of elastography and magnetic resonance imaging in patients with NAFLD: A systematic review and meta-analysisEmmanuel Anandraj Selvaraj, Ferenc Emil Mózes, Arjun Narayan Ajmer Jayaswal, et al.
Hepatology Communications|April 12, 2022
Variants in mitochondrial amidoxime reducing component 1 and hydroxysteroid 17-beta dehydrogenase 13 reduce severity of nonalcoholic fatty liver disease in children and suppress fibrotic pathways through distinct mechanismsChristian A Hudert, Leon A Adams, Anna Alisi, et al.
Hepatology (Baltimore, Md.)|March 25, 2022
Reliability of histologic assessment for NAFLD and development of an expanded NAFLD activity scoreRish K Pai, Vipul Jairath, Malcolm Hogan, et al.
Nature Communications|July 1, 2014
TM6SF2 rs58542926 influences hepatic fibrosis progression in patients with non-alcoholic fatty liver diseaseYang-Lin Liu, Helen L Reeves, Alastair D Burt, et al.
Nature|July 6, 2018
Author Correction: Inflammation-induced IgA<sup>+</sup> cells dismantle anti-liver cancer immunityShabnam Shalapour, Xue-Jia Lin, Ingmar N Bastian, et al.
Pageof 27

Showing results (191-200 of 261) with videos related to

Sort By:
Pageof 27
Cancers|April 3, 2021
A <i>PDCD1</i> Role in the Genetic Predisposition to NAFLD-HCC?Nardeen Eldafashi, Rebecca Darlay, Ruchi Shukla, et al.
The Lancet. Gastroenterology & Hepatology|August 9, 2020
A blood-based biomarker panel (NIS4) for non-invasive diagnosis of non-alcoholic steatohepatitis and liver fibrosis: a prospective derivation and global validation studyStephen A Harrison, Vlad Ratziu, Jérôme Boursier, et al.
The American Journal of Gastroenterology|May 27, 2020
Presence of Serum Antinuclear Antibodies Does Not Impact Long-Term Outcomes in Nonalcoholic Fatty Liver DiseaseRamy Younes, Olivier Govaere, Salvatore Petta, et al.
Nature Medicine|July 21, 2025
Modulation of metabolic, inflammatory and fibrotic pathways by semaglutide in metabolic dysfunction-associated steatohepatitisMaximilian Jara, Jenny Norlin, Mette Skalshøi Kjær, et al.
Canadian Liver Journal|August 22, 2022
Current considerations for clinical management and care of non-alcoholic fatty liver disease: Insights from the 1st International Workshop of the Canadian NASH Network (CanNASH)Giada Sebastiani, Keyur Patel, Vlad Ratziu, et al.
Journal of Hepatology|May 15, 2021
Diagnostic accuracy of elastography and magnetic resonance imaging in patients with NAFLD: A systematic review and meta-analysisEmmanuel Anandraj Selvaraj, Ferenc Emil Mózes, Arjun Narayan Ajmer Jayaswal, et al.
Hepatology Communications|April 12, 2022
Variants in mitochondrial amidoxime reducing component 1 and hydroxysteroid 17-beta dehydrogenase 13 reduce severity of nonalcoholic fatty liver disease in children and suppress fibrotic pathways through distinct mechanismsChristian A Hudert, Leon A Adams, Anna Alisi, et al.
Hepatology (Baltimore, Md.)|March 25, 2022
Reliability of histologic assessment for NAFLD and development of an expanded NAFLD activity scoreRish K Pai, Vipul Jairath, Malcolm Hogan, et al.
Nature Communications|July 1, 2014
TM6SF2 rs58542926 influences hepatic fibrosis progression in patients with non-alcoholic fatty liver diseaseYang-Lin Liu, Helen L Reeves, Alastair D Burt, et al.
Nature|July 6, 2018
Author Correction: Inflammation-induced IgA<sup>+</sup> cells dismantle anti-liver cancer immunityShabnam Shalapour, Xue-Jia Lin, Ingmar N Bastian, et al.
Pageof 27